Creative Testing Solutions

EIN: 271120123 501(c)(3) Public Safety

TEMPE, AZ

Total Revenue
$493,536,861
Total Expenses
$431,234,978
Total Assets
$257,226,269
Net Assets
$157,676,013
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
2009
Legal Domicile
AZ
Phone
6023437016
Tax Period
2023-01-01 to 2023-12-31

Creative Testing Solutions, founded in 2009, is a major nonprofit in the Public Safety sector that reported $493.5M in total revenue in fiscal year 2023. Revenue grew 12% year-over-year, indicating healthy expansion. Expenses of $431.2M left a modest 13% surplus.

Mission

TO PROVIDE EXCEPTIONAL CUSTOMIZED LABORATORY TESTING SERVICES TO SUPPORT THE HOSPITALS AND OTHER HEALTHCARE ORGANIZATIONS WITH THEIR LIFE SAVING MISSIONS.

Program Service Accomplishments

Program 1
Expenses: $403,143,199 Revenue: $490,518,370

DONOR TESTING BLOOD DONOR AND PLASMA TESTING SERVICES PROVIDED BY CREATIVE TESTING SOLUTIONS ("CTS") ARE ESSENTIAL TO ENSURING THE SAFETY OF THE NATION'S BLOOD AND PLASMA SUPPLY. THESE TESTING...

Read more

DONOR TESTING BLOOD DONOR AND PLASMA TESTING SERVICES PROVIDED BY CREATIVE TESTING SOLUTIONS ("CTS") ARE ESSENTIAL TO ENSURING THE SAFETY OF THE NATION'S BLOOD AND PLASMA SUPPLY. THESE TESTING ACTIVITIES ARE ABSOLUTELY NECESSARY AND MANDATED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") TO PROVIDE A SAFE BLOOD PRODUCT FOR TRANSFUSION TO PATIENTS AND TO ENSURE SAFETY OF PLASMA PRODUCTS. DUE TO THE SIGNIFICANT HEALTH RISKS ASSOCIATED WITH THE USE OF HUMAN BLOOD AND BLOOD COMPONENTS, IT IS CRITICAL FOR PUBLIC SAFETY PURPOSES THAT BLOOD BE PROPERLY TESTED BEFORE BEING INTRODUCED INTO THE HEALTHCARE SYSTEM FOR USE BY PATIENTS. A SAFE BLOOD SUPPLY IS CRITICAL TO THE WELL-BEING OF THE NATION'S HEALTHCARE SYSTEM AND ITS PATIENTS. THE SIGNIFICANCE OF THE TESTING OF BLOOD FOR PUBLIC SAFETY IS EVEN MORE PRONOUNCED IN THIS AGE OF THREATS FROM PANDEMICS AND TERRORISM. CREATIVE TESTING SOLUTIONS OPERATED EIGHT DONOR TESTING LABORATORIES IN 2023. OUR FIRST ESTABLISHED LABORATORY IS IN TEMPE, ARIZONA. THE ADDITIONAL LABORATORIES ARE LOCATED IN BEDFORD, TEXAS, CHARLOTTE, NORTH CAROLINA, ST. LOUIS, MISSOURI, ST. PETERSBURG, FLORIDA, SAN MARCOS, TEXAS, AUSTIN, TEXAS, AND MEMPHIS, TENNESSEE. THESE LOCATIONS ARE STRATEGICALLY POSITIONED NEAR MAJOR AIRPORTS IN PHOENIX, DALLAS, CHARLOTTE, ST. LOUIS AND TAMPA. THE FIVE DTL LABORATORIES ARE FOOD AND DRUG ADMINISTRATION (FDA) REGISTERED FACILITIES AND HOLD CURRENT CERTIFICATIONS FOR THE CLINICAL LABORATORY IMPROVEMENT ACT (CLIA) AS WELL AS ACCREDITATION WITH THE AMERICAN ASSOCIATION OF BLOOD BANKS (AABB), THE NEW YORK STATE DEPARTMENT OF HEALTH, CALIFORNIA DEPARTMENT OF HEALTH SERVICES AND STATE OF FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION. IN ADDITION TO DONOR SPECIMEN TESTING, THE LABORATORIES PARTICIPATE IN CLINICAL EVALUATION OF REAGENTS, TEST KITS, AND EQUIPMENT. CTS PROVIDES THE HIGHEST QUALITY IN TESTING AND SERVICE. THE LABORATORIES MAINTAIN INTERNAL QUALITY CONTROL PROGRAMS AND PARTICIPATE VOLUNTARILY IN EXTERNAL QUALITY CONTROL PROGRAMS. BLOOD SPECIMENS ARE PROCESSED UTILIZING STATE OF THE ART TECHNOLOGY WITH FDA LICENSED TEST KITS AND REAGENTS. ALL LABORATORIES ARE EQUIPPED WITH MULTIPLE AND REDUNDANT INSTRUMENTS REQUIRED FOR ROUTINE PROCESSING. ADDITIONALLY, EACH FACILITY ACTS AS A BACKUP LABORATORY TO THE OTHER CTS LABS. SPECIAL TESTING OUR SPECIAL TESTING LABORATORY IN THE PHOENIX AREA PERFORMS CONFIRMATORY AND SUPPLEMENTAL TESTING OF DONOR SAMPLES AS WELL AS NON-DONATION TESTING SUCH AS DONOR RE-ENTRY, POST EXPOSURE AND DONOR FOLLOW-UP. IT ALSO PROVIDES TESTING FOR EYE BANKS, TISSUE BANKS AND CORD BLOOD CENTERS. THE SPECIAL TESTING LABORATORIES ALSO COMPLY WITH CLIA, FDA, CA, NY, MD, AND FL STATE REGULATIONS. COMPONENT QUALITY CONTROL OUR COMPONENT QUALITY CONTROL LABORATORY IN PHOENIX PROVIDES BLOOD COMPONENT QUALITY CONTROL TESTING. RESIDUAL WHITE BLOOD CELL (RWBC) COUNTS ARE PERFORMED ON LEUKOREDUCED PRODUCTS. FACTOR VIII AND FIBRINOGEN ASSAYS ARE PERFORMED ON CRYOPRECIPITATE AND PLASMA PRODUCTS. BACTERIA DETECTION IS PERFORMED ON APHERESIS PLATELETS.

Program 2
Expenses: $2,490,070 Revenue: $2,592,893

RESEARCH AND DEVELOPMENT THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCEINTIFIC RESEARCH. THE CTS RESEARCH PROGRAM FOCUSES ON THE...

Read more

RESEARCH AND DEVELOPMENT THE CTS RESEARCH PROGRAM IS DEDICATED TO ADVANCING BLOOD SAFETY AND EVIDENCE-BASED TRANSFUSION PRACTICES THROUGH SCEINTIFIC RESEARCH. THE CTS RESEARCH PROGRAM FOCUSES ON THE DEVELOPMENT AND/OR EVALUATION OF NEW BLOOD DONOR SCREENING TECHNOLOGIES WHICH SIGNIFICANTLY IMPROVE AND PROMOTE BLOOD SAFETY IN THE AREAS OF INFECTIOUS DISEASE, IMMUNOLOGY, MOLECULAR DIAGNOSTICS, AND EPIDEMIOLOGY. ADDITIONALLY, THE CTS RESEARCH PROGRAM SERVES AS THE FOCUS FOR A MULTI-INSTITUTIONAL CONSORTIUM WHICH COLLECTS AND INTEGRATES TESTING DATA FROM APPROXIMATELY 75% OF THE US BLOOD SUPPLY FOR THE PURPOSE OF NATIONAL HAEMOVIGILANCE, HORIZON SCANNING FOR EMERGING INFECTIOUS DISEASES RELEVANT TO BLOOD SAFETY, AND PROVIDING CRITICAL INFORMATION FOR THE EVALUATION OF BEST PRACTICES IN TRANSFUSION MEDICINE, THE PROMOTION OF DONOR HEALTH, AND THE IMPROVEMENT OF TRANSFUSION RECIPIENT OUTCOMES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $0
Program Service Revenue $493,111,263
Investment Income $425,598
Other Revenue $0
TOTAL REVENUE $493,536,861

Expense Breakdown

Grants Paid $0
Salaries & Benefits $100,718,465
Fundraising Expenses $0
Program Expenses $405,633,269
Other Expenses $330,516,513
TOTAL EXPENSES $431,234,978

Year-over-Year Comparison

2023 2022 Change
Revenue $493,536,861 $438,773,486 +0.1%
Expenses $431,234,978 $396,704,355 +0.1%
Net Income $62,301,883 $42,069,131 +0.5%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
11
Independent Members
11
Employees
1404
Volunteers
11

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
9
$2,977,662
Total Directors
11
$0
Key Employees
6
$1,901,413
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
N/A DIRECTOR/CHAIR 1.0
Officer Director
$0 $0 $0
N/A DIRECTOR/SECRETARY-TREASURER 1.0
Officer Director
$0 $0 $0
N/A DIRECTOR/VICE-CHAIR 1.0
Officer Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A DIRECTOR 1.0
Director
$0 $0 $0
N/A GENERAL COUNSEL/ASST SECRETARY 8.0
Officer
$39,560 $4,715 $44,275
N/A CHIEF OPERATING OFFICER (THRU 04/04/23) 45.0
Officer
$383,734 $24,963 $408,697
N/A CHIEF INFORMATION OFFICER 45.0
Officer
$352,160 $50,176 $402,336
N/A CHIEF OPERATING OFFICER 45.0
Officer
$596,593 $33,010 $629,603
N/A PRESIDENT/CEO 45.0
Officer
$887,331 $33,529 $920,860
N/A CHIEF FINANCIAL OFFICER 45.0
Officer
$529,293 $42,598 $571,891
N/A VP, QUALITY IMPROVEMENT 45.0
Key Emp
$313,415 $42,479 $355,894
N/A VP, Human Resources 45.0
Key Emp
$264,868 $45,149 $310,017
N/A VP, Operations 45.0
Key Emp
$310,850 $27,053 $337,903
N/A VP, SCIENTIFIC AFFAIRS 45.0
Key Emp
$296,262 $24,345 $320,607
N/A SENIOR DIRECTOR, STRATEGIC INITIATIVES 45.0
Key Emp
$221,095 $23,886 $244,981
N/A VP, SOURCE PLASMA OPERATIONS 45.0
Key Emp
$303,732 $28,279 $332,011
N/A DIRECTOR, OPERATIONS II 45.0
Highest
$261,895 $20,988 $282,883
N/A DIRECTOR, OPERATIONS II 45.0
Highest
$250,611 $23,560 $274,171
N/A DIRECTOR, OPERATIONS II 45.0
Highest
$265,778 $21,327 $287,105
N/A DIRECTOR, OPERATIONS II 45.0
Highest
$275,879 $36,764 $312,643
N/A SENIOR DIRECTOR, APPLICATIONS 45.0
Highest
$272,628 $24,667 $297,295
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 No data No data No data No data
2023 $493,536,861 $431,234,978 $257,226,269 $62,301,883
2022 $438,773,486 $396,704,355 $202,650,150 $42,069,131
2021 $369,133,933 $327,070,326 $144,759,608 $42,063,607
2020 $405,650,488 $374,330,027 $151,303,891 $31,320,461
2019 $409,465,869 $370,122,158 $186,188,612 $39,343,711
2018 $434,869,430 $404,083,640 $165,158,769 $30,785,790
Explore More Nonprofits
Top 100 Nonprofits in Arizona Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare Creative Testing Solutions with other nonprofits in Arizona and across the country.